Educational guide

Anti-inflammatory therapy shows promise to treat patients following acute myocardial infarction

Written by Peptide Therapy Guide Editorial TeamPublished September 7, 2026

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Research into the protective effects of two anti-inflammatory molecules, transforming growth factor-beta1 (TGFβ1) and Heligmosomoides polygyrus TGM (HpTGM), following heart attack found that both proteins reduced the inflammatory response within the injured heart and reduced mature scarring. Anti-inflammatory therapy to treat patients following acute myocardial infarction is an exciting prospect that deserves further translational studies, report investigators in The American Journal of Pathology, published by Elsevier.

Patients with acute heart attacks (ST elevation myocardial infarction, or STEMI) are very likely to survive if they undergo timely reopening of the occluded coronary artery (coronary reperfusion) in specialized clinical centers. Despite the given survival rates and major improvements in treatment, progression to heart failure still represents a major clinical problem. The patients' longer-term outcomes depend on the extent of the damage to their heart tissue.

Lead investigator Helen M. Arthur, PhD, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, explains: "Coronary reperfusion after STEMI is standard therapy to salvage ischemic heart muscle. However, evidence suggests that the subsequent inflammatory response that the body initiates to repair the damaged heart tissue can also cause further loss of viable heart muscle. The more muscle that is lost, the greater the risk of subsequent progression to heart failure. The reason for this study was to investigate the potential protective effects of TGFβ1 as a possible intervention to minimize this additional damage to the heart beyond the ischemic damage caused by the heart attack itself."

The research team found that levels of an important anti-inflammatory protein TGFβ1 in the blood of STEMI patients 24 hours after reperfusion correlated with a reduction in infarct size after three months. To investigate this further they used an established mouse model of a heart attack to test the protective effects of TGFβ1, a protein known to be released in the body in response to tissue injury. They also studied its mimic HpTGM, a protein produced by a parasitic worm to help evade the immune response and thereby enable the worm to live within the tissue lining the gut. Intravascular delivery of either of these naturally occurring anti-inflammatory proteins reduced the injurious inflammatory response within the heart and importantly, the extent of heart injury as evidenced by reduced mature scar size.

The investigators were surprised to find almost identical beneficial effects of TGFβ1 and HpTGM treatment. Although TGFβ1 and HpTGM are evolutionarily unrelated, both these molecules interact with cells in a similar manner by activating the same signalling pathway. The dose of anti-inflammatory therapy was given at the time of reperfusion, which corresponds to a clinically useful time for a therapeutic intervention in humans.

Investigators could attribute the beneficial outcomes to the protective effect of these molecules on endothelial cells - the cells lining the blood vessels that help to regulate the exit of proinflammatory white blood cells from the circulation and enter the injured tissue. TGFβ1 has well-established anti-inflammatory properties, whereas HpTGM is a parasitomimetic with great clinical potential. Recent work in the Maizels laboratory at the University of Glasgow has also shown that delivery of HpTGM has a major anti-inflammatory effect in mouse models of colitis or airway inflammation, taking advantage of the product evolved by a parasite to quell the immune response to its presence.

Dr. Arthur concluded: "The current study shows that exogenous delivery of HpTGM at the time of coronary artery reperfusion dampens the proinflammatory response of coronary endothelial cells and reduces cardiac injury, leading to increased myocardial salvage and reduced scar size with the corollary of improved prospects for long-term cardiac function. The use of HpTGM as an anti-inflammatory therapy in treating heart attack patients is clearly an exciting prospect that requires further translational studies."

Redgrave, R. E., et al. (2023). Exogenous Transforming Growth Factor-β1 and Its Mimic Heligmosomoides polygyrus TGM Attenuate the Heart’s Inflammatory Response to Ischemic Injury and Reduce Mature Scar Size. The American Journal of Pathology. doi.org/10.1016/j.ajpath.2023.09.014.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01The answer isn't "yes" for everyone. Here's what you need to know about it.

Many diseases are marked by chronic inflammation — the persistent activation of the immune system. Although we have lots of medications to quiet acute (short-term) inflammation — like an attack of gout — they're not often effective in preventing chronic inflammation. And some people don't realize that. "I've had patients come in and say, 'I keep reading that inflammation is a killer. Can you give me something for it?' There's a lot of misconception about it," notes Dr. Robert Shmerling, a rheumatologist and medical editor of the Harvard Special Health Report Fighting Inflammation (/ui).

Source: www.health.harvard.edu ↗

02How has this work been used to devise a simple malignancy indicator for detecting breast cancer, and what impact has this led to when you looked clinically?

We recently proposed that there is a possible test as a malignancy indicator using the ratio of certain D and L-amino acids, which seemed to work in the limited cell growth media that we were working in. However, it needs to be tested further and in more detail before any clinical applications are forthcoming. Image Credit:Shutterstock/CI Photos

Source: www.news-medical.net ↗

03Your early research focused on predicting molecular properties such as solubility using machine learning. What did that teach you about data-driven property prediction?

Data-driven models, such as Quantitative Structure Activity Relationships (QSAR), are incredibly attractive because they offer rapid methods for predicting molecular properties, including those that are difficult to access through fundamental chemical and physical theory. For new molecules, in related regions of chemical space to the training data, they can often be very accurate. The challenge is that they typically do not generalize across large diverse chemical and biological spaces. Therefore real care is needed when applying them to novel chemistry or biology. Some attempts to build more widely applicable QSAR models have been made in recent years, but most models in use today are still built for specific chemistries and properties owing to the scale and complexity of chemical space. When I started this work, especially for solubility predictions, the datasets were modest by today’s standards, often hundreds to a few thousand molecules. One of the first things that teaches you is to explore the data carefully, assess its quality and quantity, and only then move forward with modeling. The aim is to capture genuine relationships between numerical molecular descriptions and important target endpoints, but those relationships may be only locally generalizable. I also think the phrase “simple descriptors” is interesting. Some are simple, such as atom counts or bond counts, but others rely on detailed parameterization, group contributions, and graph-theoretical techniques. We still see these descriptors used today, sometimes alongside embeddings from graph neural networks or language models. The main lesson for me is that there is no single workflow. Each dataset, model, and end-use case needs careful thought.

Source: www.news-medical.net ↗

04Finally, how do you envision the future of drug discovery and development in relation to your research on axon biology and sncRNAs?

I foresee a shift where RNA will gain more traction, considering recent successes in RNA-based therapies. Given the role sncRNAs play in axons, our research aligns well with this trend. By understanding the axonal RNA biology, we can pave the way for targeted therapies that could revolutionize how we approach various neurological conditions.

Source: www.news-medical.net ↗

05What are the basic motifs of proteins?

The simplest motifs are composed of multiple secondary structure units. These simple motifs can contain α-helices and β-sheets that are layered adjacent to one another either in the same direction (parallel) or in the opposite direction (anti-parallel). The simplest motif is the formation of a “loop”, known as a β-turn if it is short, while an unstructured connection is termed a “coiled region”.

Source: www.news-medical.net ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Related questions

Peptide Therapy Guide Editorial Team

What is Tubulin?

Host Cells for Producing Recombinant Proteins

Different anti-PD-L1 antibodies show varied results in tumor growth inhibition

Health Dangers of BCAA in Protein Supplements